Apimeds Pharmaceuticals US, Inc. Total Liabilities
Apimeds Pharmaceuticals US, Inc. total liabilities. Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) has total liabilities worth $14.70 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Apimeds Pharmaceuticals US, Inc. to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Apimeds Pharmaceuticals US, Inc. (2021–2025)
Total liabilities of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025. This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check Apimeds Pharmaceuticals US, Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Apimeds Pharmaceuticals US, Inc. Competitors by Total Liabilities
The table below lists competitors of Apimeds Pharmaceuticals US, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beowulf Mining PLC
ST:BEO-SDB
|
Sweden | Skr374.80K |
|
Traws Pharma Inc
NASDAQ:TRAW
|
USA | $9.78 Million |
|
Comprehensive Healthcare Systems Inc
V:CHS
|
Canada | CA$6.27 Million |
|
Azucar Minerals Ltd
V:AMZ
|
Canada | CA$127.25K |
|
Foresight Solar Fund Ltd
LSE:FSFL
|
UK | GBX1.94 Million |
|
LOBO EV TECHNOLOGIES LTD. Ordinary shares
NASDAQ:LOBO
|
USA | $13.53 Million |
|
TANTALEX LITHIUM RES.CORP
F:DW8
|
Germany | €47.44 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Apimeds Pharmaceuticals US, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see APUS current and non-current assets.
Liquidity & Leverage Metrics
Apimeds Pharmaceuticals US, Inc. Total Liabilities Ratios Explained
Apimeds Pharmaceuticals US, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apimeds Pharmaceuticals US, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apimeds Pharmaceuticals US, Inc. (2021–2025)
The table below shows the annual total liabilities of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.84 Million | +690.26% |
| 2024-12-31 | $1.37 Million | +251.40% |
| 2023-12-31 | $390.20K | -45.79% |
| 2022-12-31 | $719.78K | +75.28% |
| 2021-12-31 | $410.65K | -- |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.